PRECISION BIOSCIENCES INC Other Significant Noncash Transaction, Value of Consideration Received
PRECISION BIOSCIENCES INC (DTIL) reported Other Significant Noncash Transaction, Value of Consideration Received of $17.89 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 · last filed 2023-03-09
- PRECISION BIOSCIENCES INC other significant noncash transaction, value of consideration received for the quarter ending 2021-12-31 was $0.00.
- PRECISION BIOSCIENCES INC other significant noncash transaction, value of consideration received for fiscal 2021 was $17.89M.
| Period end | Other Significant Noncash Transaction, Value of Consideration Received 3 month | Other Significant Noncash Transaction, Value of Consideration Received 9 month | Other Significant Noncash Transaction, Value of Consideration Received 12 month |
|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $17.89M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $17.89M 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |